A Randomized, Double-Blind, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACH-0145548 in Healthy Participants
Phase of Trial: Phase I
Latest Information Update: 16 Jul 2018
At a glance
- Drugs ACH-5548 (Primary)
- Indications Unspecified
- Focus Adverse reactions; First in man
- Sponsors Achillion Pharmaceuticals
- 10 Jul 2018 According to an Achillion Pharmaceuticals media release, the company has initiated dosing the healthy volunteer in this study. Interim results from this study is anticipated in the second half of 2018.
- 10 Jul 2018 Status changed from not yet recruiting to recruiting, according to an Achillion Pharmaceuticals media release.
- 31 May 2018 New source identified and integrated (Australian New Zealand Clinical Trials Registry; ACTRN12618000896279)